14/09/2017 04:03:19

Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary Shares

OXFORD, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces the pricing of its underwritten public offering of 1,459,000 American Depositary Shares (“ADSs”) at a public offering price of $12.00 per ADS, before underwriting discounts and commissions. Each ADS represents five ordinary shares of Summit. Following the offering, the ADSs will trade on the NASDAQ Global Market.

In addition, Summit has granted the underwriters an option for a period of 30 days to purchase, at the public offering price less underwriting discounts and commissions, up to an additional 218,850 ADSs. Gross proceeds from the offering are expected to be approximately $17.5 million (or approximately $20.1 million if the underwriters exercise in full their option to purchase additional ADSs). Closing of the offering is expected to occur on or about 18 September 2017, subject to customary closing conditions.

Canaccord Genuity Inc. and JMP Securities LLC are acting as joint lead book-running managers for the offering. Needham & Company, LLC is acting as lead manager and H.C. Wainwright & Co., LLC is acting as co-manager.

The securities are being issued and sold pursuant to an effective shelf registration statement (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on 13 September 2017. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting Canaccord Genuity Inc., Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, Massachusetts 02110, telephone: +1 (617) 371-3900 or JMP Securities LLC, Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, telephone: +1 (415) 835- 8985.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. In particular, and without limitation, no offer of securities to the public (as that term is understood in the EU Prospectus Directive) is being made in the United Kingdom or in any other country in the European Economic Area which has implemented the EU Prospectus Directive.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

For more information, please contact:

Summit

Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office) 

Tel: +44 (0)1235 443 951

       +1 617 225 4455

Forward Looking Statements

Any statements in this press release about Summit’s future expectations, plans and prospects, including but not limited to, statements about whether or not Summit will consummate the offering and the anticipated use of the proceeds from the offering, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market conditions, the satisfaction of customary closing conditions, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from on-going and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for Summit’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” section of filings that Summit makes with the Securities and Exchange Commission, including Summit’s Annual Report on Form 20-F for the fiscal year ended January 31, 2017. Accordingly, readers should not place undue reliance on forward looking statements or information. In addition, any forward-looking statements included in this press release represent Summit’s views only as of the date of this release and should not be relied upon as representing Summit’s views as of any subsequent date. Summit specifically disclaims any obligation to update any forward-looking statements included in this press release.

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Nov
ALMB
Når man dagligt læser indlæg fra Alpehuen, Mackkeith, Malurt, EMEA (MENA), Powertrade som via en flo..
30
17 Nov
PNDORA
Om nogen, har jeg ikke meget tilovers for GW, men jeg har tilladt mig at anmelde dit indlæg. Nu må i..
29
16 Nov
NOVO-B
Og Goodwrench, Baronen og marc55
25
20 Nov
I:SP500
God aften   Gå lige ind under Conference Board i USA og læs, at de ledende indikatorer steg med hele..
23
17 Nov
OMXC20
  Her kommer en kort gennemgang og forklaring på, hvorfor aktietilbagekøb både kan være rigtig godt ..
23
20 Nov
VWS
Roland, nu må du simpelthen stoppe. Det her er simpelthen for ynkeligt, hvordan kan du være så selvi..
21
18 Nov
I:NDX
Der er efterhånden alt for få på EI, der bruger hovedparten af deres tid på at tjene penge på aktier..
18
19 Nov
PNDORA
Hvad skal vi med millionærklubben når vi har roland333 
17
18:27
PNDORA
Hej Roland.   Dem du prøver at råde om aktiehandel, fortjener at vide hvilken tåbe, der prøver at rå..
16
16 Nov
VWS
Lavede en kæmpe fodfejl med Vestas. Købte i den private frie pot 1200 stk med gak 402,8 fordi jeg..
15

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

21/11/2017 15:35:27
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

21/11/2017 13:37:22
ALLIANCE TRUST PLC                                    At the close of business on Monday 20 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.0p -       including income, 787.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Admiral Group PLC : Holding(s) in Company

21/11/2017 10:20:10
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
2
Novea Inc.'s Captive Insurance Subsidiary Jacana Insurance Engages Madison RE I.I. to Provide Reinsurance for Jacana Warranty Offerings
3
ICTV Brands Reports 3Q17 Financial Results
4
Aryaka to Present Global SD-WAN Use Cases and Enterprise Deployment Stories at 6th Annual CIO Leaders Singapore Summit
5
Zomedica Pharmaceuticals Corp. Registration Statement Declared Effective by U.S. Securities and Exchange Commission

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 November 2017 21:01:21
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171108.1 - EUROWEB3 - 2017-11-21 22:01:21 - 2017-11-21 21:01:21 - 1000 - Website: OKAY